Jyoti Palaniappan net worth and biography

Jyoti Palaniappan Biography and Net Worth

Jyoti Palaniappan is the Senior Vice President, Diagnostics, T-Detect of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining Adaptive, Jyoti served as the Chief Commercial Officer for Bigfoot Biomedical, a diabetes digital health company, from 2018, and as a commercial executive in a variety of roles at Abbott, a public diversified healthcare company, from 2007. Jyoti holds a BS in Biology from University of Michigan and an MBA/MPH from Emory University.

What is Jyoti Palaniappan's net worth?: The estimated net worth of Jyoti Palaniappan is at least $58,559.73 as of July 19th, 2021. Mr. Palaniappan owns 9,809 shares of Adaptive Biotechnologies stock worth more than $58,560 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Palaniappan may own. Learn More about Jyoti Palaniappan's net worth.
How do I contact Jyoti Palaniappan?: The corporate mailing address for Mr. Palaniappan and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Jyoti Palaniappan's contact information.
Has Jyoti Palaniappan been buying or selling shares of Adaptive Biotechnologies?: Jyoti Palaniappan has not been actively trading shares of Adaptive Biotechnologies in the last ninety days. Most recently, Jyoti Palaniappan sold 651 shares of the business's stock in a transaction on Monday, July 19th. The shares were sold at an average price of $36.12, for a transaction totalling $23,514.12. Following the completion of the sale, the senior vice president now directly owns 9,809 shares of the company's stock, valued at $354,301.08. Learn More on Jyoti Palaniappan's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Jyoti Palaniappan Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/19/2021	Sell	651	$36.12	$23,514.12	9,809
5/18/2021	Sell	651	$35.00	$22,785.00	9,809
4/19/2021	Sell	1,301	$41.25	$53,666.25	10,459
3/18/2021	Sell	16,052	$43.58	$699,546.16	25,210

Jyoti Palaniappan Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $5.97

$5.81

$6.88

50 Day Range

MA: $5.43

$4.40

$6.78

2 Week Range

Now: $5.97

$2.28

$7.07

Volume

1,720,949 shs

Average Volume

1,413,251 shs

Market Capitalization

$881.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW